Physician profile
Gene Ong
NPI 1659365286
$10,811.94
in general payments reported to CMS, 2019-2025
31 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $755 · 2021: $956 · 2022: $1,739 · 2023: $1,690 · 2024: $2,381 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,334 · Education: $70.83 · Travel and Lodging: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,333.83 |
| Education | $70.83 |
| Travel and Lodging | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,030.00 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $1,069.31 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $980.66 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $859.09 | 2021-2025 | |
| Amgen INC. | $746.94 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $616.11 | 2022-2025 | |
| Glaxosmithkline, LLC. | $536.40 | 2020-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $526.36 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $428.35 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $415.73 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $367.09 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $347.86 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.87 | 2023-2025 | Jardiance, Synjardy |
| Mallinckrodt Hospital Products INC. | $250.83 | 2020-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $227.20 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $148.58 | 2020-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $137.73 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $122.86 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $119.22 | 2022-2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $82.70 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.68 | 2020-2024 | Gattex |
| Ardelyx, INC. | $63.50 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $63.33 | 2023-2024 | Jynarque |
| Lilly USA, LLC | $60.28 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $54.85 | 2023-2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $37.52 | 2020-2022 | |
| Kyowa Kirin, INC. | $37.34 | 2023-2024 | Crysvita |
| Azurity Pharmaceuticals, INC. | $20.72 | 2025 | Edarbyclor |
| Ultragenyx Pharmaceutical INC. | $18.47 | 2023 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| Cormedix INC. | $14.48 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.